ReviewPulmonary therapy2021
A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists.
Review in Pulmonary therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06635863 (Immunosuppression Versus Medical Therapy for UN-explained Low Ejection Fraction and VT), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunosuppression Versus Medical Therapy for UN-explained Low Ejection Fraction and VT
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Infliximab in neurosarcoidosis: a systematic review and meta-analysis.Annals of clinical and translational neurology · 2024Pooled it
- The onset of sarcoidosis in relation to tattoos: Focus on the treatment landscape. A critical literature review and case report.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Predictive value of baseline serum angiotensin-converting enzyme (sACE) levels for steroid response in sarcoidosis.Lung India : official organ of Indian Chest Society · 2026Article
- Endogenous Hypersensitivity Infection: A Unifying Framework forMicroorganisms · 2026Review
- Hepatic and Splenic Sarcoidosis Without Lymphadenopathy: An Atypical Multisystem Presentation.Cureus · 2026Article
- Article
- βc receptor antagonism mitigates sarcoidosis granuloma formation by targeting inflammatory signals and aberrant lipid metabolism.Frontiers in immunology · 2025Article
- Gastrointestinal sarcoidosis mimicking malignancy: A confusing scenario.Caspian journal of internal medicine · 2025Article
- Sarcoidosis associated massive pleural Effusion: Case report and literature review.Respiratory medicine case reports · 2025Article
- A Rare Case of Sarcoidosis Presenting as an Isolated Breast Mass and Pain: A Case Report and Literature Review.The American journal of case reports · 2023Review
- Use of TYK2 inhibitor to relieve reactive granulomatous dermatitis due to myelodysplastic syndrome.JAAD case reports · 2023Article
- Ocular sarcoidosis in adults and children: update on clinical manifestation and diagnosis.Journal of ophthalmic inflammation and infection · 2023Review
- The Great Imitator: A Case of Multisystem Sarcoidosis Involving the Genitourinary System.Cureus · 2023Article
- Sarcoidosis lung transplantation waitlist mortality, a national registry database study.ERJ open research · 2023Article
- Why so low? An unusual case of myositis in a child.Pediatric rheumatology online journal · 2023Article
- Safety of corticosteroid therapy in sarcoidosis treatment.Frontiers in drug safety and regulation · 2023Review
- The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era.Rheumatology international · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to frequent lung involvement, the pulmonologist is often the reference physician for management of sarcoidosis, a systemic granulomatous disease with a heterogeneous course. Treatment of sarcoidosis raises some issues. The first challenge is to select patients who are likely to benefit from treatment, as sarcoidosis may be self-limiting and remit spontaneously, in which case treatment can be postponed and possibly avoided without any significant impact on quality of life, organ damage or prognosis. Systemic glucocorticosteroids (GCs) are the drug of first choice for sarcoidosis. When GCs are started, there is a > 50% chance of long-term treatment. Prolonged use of prednisone at > 10 mg/day or equivalent is often associated with severe side effects. In these and refractory cases, steroid-sparing options are advised. Antimetabolites, such as methotrexate, are the second-choice therapy. Biologics, such as anti-TNF and especially infliximab, are third-choice drugs. The three treatments can be used concomitantly. Regardless of whether treatment is started, the clinician needs to organize regular follow-up to monitor remissions, flares, progression, complications, toxicity and relapses in order to promptly adjust the drugs used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.